13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC

(a)

¨

Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);

(b)

¨

Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

¨

Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

¨

Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

x

Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

(f)

¨

Employee benefit plan or endowment fund in accordance
with

Rule 13d-1(b)(1)(ii)(F);

(g)

x

Parent holding company or control person in
accordance with

Rule 13d-1(b)(1)(ii)(G);

(h)

¨

Savings association as defined in Section 3(b)
of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

¨

Church plan that is excluded from the definition
of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

(j)

¨

Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);

(k)

¨

Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

13G Filing: Matrix Capital Management and Adaptimmune Therapeutics PLC – ADR (ADAP)

Item 2(e).	CUSIP NUMBER:

	There is no CUSIP number assigned to the Shares. CUSIP number 00653A107 has been assigned to the ADSs of the Company. Each ADS represents 6 Shares.